Apimeds Pharmaceuticals US, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Assets | |||
| Cash & Equivalents | $1.6M | $3.5K | $410.5K |
| Accounts Receivable | — | — | — |
| Inventory | — | — | — |
| Total Current Assets | $14.0M | $13.1K | $422.1K |
| Property, Plant & Equipment | $51.6K | — | — |
| Goodwill | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — |
| Total Assets | $164.2M | $13.1K | $422.1K |
| Liabilities | |||
| Accounts Payable | — | $591.2K | $54.4K |
| Total Current Liabilities | $10.7M | $1.0M | $123.3K |
| Long-Term Debt | — | — | — |
| Total Liabilities | $10.8M | $1.4M | $390.2K |
| Stockholders' Equity | |||
| Retained Earnings | $-10.4M | $-4.4M | $-3.0M |
| Total Stockholders' Equity | $153.3M | $-1.4M | $31.9K |